Cytotheryx is a preclinical cell therapy company focused on addressing liver disease by mass-producing functional human hepatocytes. Its proprietary bio-incubator platform enables scalable cell production for multiple applications, including a bioartificial liver support system for acute liver failure and universal liver cells intended for transplantation. The company also aims to supply hepatocytes for drug discovery and toxicity testing, broadening its commercial potential. Headquartered in Rochester, Minnesota, Cytotheryx leverages Mayo Clinic–derived science and an experienced management team. The newly secured capital will fund manufacturing scale-up, facility expansion to GMP standards, and regulatory pathway planning as the firm moves programs toward first-in-human studies. While still pre-revenue, Cytotheryx positions itself as a critical enabler in the liver-disease treatment landscape, targeting significant unmet clinical needs.

Total raised

$60M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2026